Majority of providers have no plans for Stage 2 attestation this year

More than half (55 percent) of physicians do not plan to attest to Meaningful Use Stage 2 in 2015, according to a survey of almost 2,000 members of SERMO, a social network for physicians.

Respondents cited “patient engagement, lack of workflow usability and excessive time consumption” as their reasons for not attesting.

Centers for Medicare & Medicaid Services (CMS) figures reveal that only 4 percent (16,455) of eligible professionals have attested to Stage 2 as of Dec. 1. As a result, multiple efforts have sprung up to add greater flexibility to the program. More than 250,000 providers will face financial penalties and Medicare payment reductions this year.

The American Medical Association, for one, has called for CMS to take immediate action to add more flexibility and shorten the reporting period to help physicians avoid penalties.  

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.